Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma

Abstract

The standard definition of platinum-resistant ovarian cancer or primary peritoneal carcinoma commonly includes patients whose disease initially responded to a platinum-based combination regimen, but recurred less than 6 months after the completion of primary therapy. Recent experience with several patients with these malignancies treated in the Gynecologic Cancer Program of the Cleveland Clinic Foundation, whose disease recurred within this period but who subsequently responded to platinum therapy, calls into question the validity and clinical relevance of this commonly employed definition, both for the conduct of phase 2 trials of new agents in ovarian cancer and primary peritoneal carcinoma, and for the standard management of women in this clinical setting.

This is a preview of subscription content, log in to check access.

Author information

Additional information

Received: 9 February 1998 /  Accepted: 20 March 1998

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Markman, M., Kennedy, A., Webster, K. et al. Evidence that a “treatment-free interval of less than 6 months” does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 124, 326–328 (1998). https://doi.org/10.1007/s004320050177

Download citation

  • Key words Ovarian cancer
  • Platinum resistance
  • Peritoneal carcinoma
  • Treatment-free interval